Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Urology | Family Medicine
 Disease Category: Urothelial Tract Cancer
Location: United States, CO

Trial Information

Phase II, open-label study evaluating DN24-02 as adjuvant therapy in subjects with high risk HER2+ urothelial carcinoma.

High grade urothelial cancer to be treated with a novel immunotherapy given intravenously.

Candice Fortuna-Smith
The Urology Center of Colorado
2777 Mile High Stadium Cir
Denver, CO 80211
Phone: 303-421-5783
Fax: 303-421-1318
Email: cfortuna@tucc.com

View Map

Research Center Information: The Urology Center of Colorado

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.